AZN.UK

11,376

+1.61%↑

GSK

1,460

+2.13%↑

HLN.UK

395

+2.12%↑

AZN.UK

11,376

+1.61%↑

GSK

1,460

+2.13%↑

HLN.UK

395

+2.12%↑

AZN.UK

11,376

+1.61%↑

GSK

1,460

+2.13%↑

HLN.UK

395

+2.12%↑

AZN.UK

11,376

+1.61%↑

GSK

1,460

+2.13%↑

HLN.UK

395

+2.12%↑

AZN.UK

11,376

+1.61%↑

GSK

1,460

+2.13%↑

HLN.UK

395

+2.12%↑

Search

Indivior PLC

Fechado

736 -1.27

Visão Geral

Variação de preço das ações

24h

Atual

Mín

700.5

Máximo

744.5

Indicadores-chave

By Trading Economics

Rendimento

63M

66M

Vendas

-8M

299M

P/E

Médio do Setor

369.5

63.778

EPS

0.319

Margem de lucro

22.074

Funcionários

1,030

EBITDA

97M

106M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+49.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

24 de abr. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-2.8M

933M

Abertura anterior

737.27

Fecho anterior

736

Indivior PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 23:55 UTC

Ações em Alta

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 de abr. de 2025, 22:50 UTC

Grandes Movimentos do Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 de abr. de 2025, 21:08 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 de abr. de 2025, 21:00 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 de abr. de 2025, 23:56 UTC

Conversa de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 de abr. de 2025, 23:44 UTC

Principais Notícias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 de abr. de 2025, 23:10 UTC

Conversa de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:57 UTC

Conversa de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 de abr. de 2025, 22:43 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 de abr. de 2025, 22:12 UTC

Conversa de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 de abr. de 2025, 21:48 UTC

Principais Notícias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 de abr. de 2025, 21:41 UTC

Conversa de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 de abr. de 2025, 21:04 UTC

Principais Notícias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 de abr. de 2025, 21:03 UTC

Conversa de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 de abr. de 2025, 20:53 UTC

Ganhos

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 de abr. de 2025, 20:52 UTC

Ganhos

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparação entre Pares

Variação de preço

Indivior PLC Previsão

Preço-alvo

By TipRanks

49.24% parte superior

Previsão para 12 meses

Média 1,104.38 GBX  49.24%

Máximo 1,225.568 GBX

Mínimo 975 GBX

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Indivior PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Indivior PLC

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.